Vaccines from age 5?

Pfizer for 5 to 11 year olds https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-results 5 to 11 years of age, the vaccine was safe, well tolerated and showed robust neutralizing antibody responses Companies plan to submit these data to the FDA, EMA and other regulatory agencies Results in children under 5 years of age are expected as soon as later this year N = 4,500, Finland, Poland, Spain, US Two dose, 21 days apart 10 ug, not 30 ug Similar results to 30 ug in 15 to 25 year olds Phase 2/3 trial Side effects reported with the vaccine include: A severe allergic reaction would usually occur within a few minutes to one hour Difficulty breathing, swelling of the face and throat, a fast heartbeat, a bad rash all over the body, dizziness, and weakness Myocarditis and pericarditis have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. chest pain shortness of breath feelings of having a fast-beating, fluttering, or pounding heart Other side effects injection site pain; tiredness; headache; muscle pain; chills; joint pain; fever; injection site swelling; injection site redness; nausea; feeling unwell; swollen lymph nodes (lymphadenopathy); diarrhea; vomiting; arm pain There is no information on the use of the vaccine with other vaccines FDA tweet about ivermectin https://twitter.com/US_FDA/status/1429050070243192839?s=20 https://twitter.com/US_FDA Infectious SARS-CoV-2 in Exhaled Aerosols and Efficacy of Masks During Early Mild Infection https://sph.umd.edu/news/covid-19-virus-evolving-get-better-becoming-airborne-new-study-shows https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab797/6370149 Epidemiology implicates airborne transmission, aerosol infectiousness Methods Confirmed cases gave: Blood, saliva, mid-turbinate and fomite (phone) swabs 30-minute breath samples while vocalizing with and without masks Up to two visits two days apart Quantified and sequenced viral RNA, cultured virus Results N = 49 seronegative cases Mean days post onset 3.8 ± 2.1 May 2020 through April 2021 Detected SARS-CoV-2 RNA in alpha variant 45% of fine (less than 5 μm) aerosols 31% of coarse ( more than 5 μm) aerosols 65% of fomite samples Masks reduced viral RNA by: 48% in fine aerosols 77% in coarse aerosols Cloth and surgical masks were not significantly different The alpha variant (compared with earlier viruses) 43-fold increase in fine aerosol viral RNA Remained a significant 18-fold increase adjusting for viral RNA in saliva, swabs, and other potential confounders Conclusion SARS-CoV-2 is evolving toward more efficient aerosol generation Loose-fitting masks provide significant but only modest source control Continued layered controls and tight-fitting masks and respirators will be necessary Learn more about your ad choices. Visit megaphone.fm/adchoices